2.1185

44.90% -1.7015

Pyxis Oncology Inc (PYXS)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché PYXS Giù? Forum Previsione

Precedente Chiudi:

$3.82

Aprire:

$2.17

Volume 24 ore:

12.84M

Relative Volume:

16.72

Capitalizzazione di mercato:

$122.20M

Reddito:

Utile/perdita netta:

$-73.79M

Rapporto P/E:

-0.746

EPS:

-2.84

Flusso di cassa netto:

$-77.44M

1 W Prestazione:

-50.82%

1M Prestazione:

-42.80%

6M Prestazione:

-47.38%

1 anno Prestazione:

+47.20%

Intervallo 1D:

$1.90

$2.39

Intervallo di 1 settimana:

$1.90

$4.40

Portata 52W:

$1.35

$6.85

Pyxis Oncology Inc Stock (PYXS) Company Profile

Nome

Pyxis Oncology Inc

Settore

Healthcare (1195)

Industria

Biotechnology (683)

Telefono

(617) 221-9059

Indirizzo

321 HARRISON AVENUE, BOSTON

Dipendente

Cinguettio

Prossima data di guadagno

2024-08-11

Ultimi documenti SEC

PYXS's Discussions on Twitter

Confronta PYXS con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
PYXS	2.125	122.20M	0	-73.79M	-77.44M	-2.84
VRTX	449.09	115.43B	10.63B	-479.80M	-1.35B	13.33
REGN	749.38	82.04B	13.85B	4.65B	3.32B	35.06
ARGX	587.39	35.30B	1.86B	-40.29M	-1.28B	-4.16
ALNY	247.66	32.04B	2.09B	-332.26M	16.06M	-4.14
BNTX	106.77	24.89B	3.30B	-501.07M	1.03B	11.54

Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2021-11-02	Iniziato	BofA Securities	Neutral
2021-11-02	Iniziato	Credit Suisse	Outperform
2021-11-02	Iniziato	Jefferies	Buy

Pyxis Oncology Inc Borsa (PYXS) Ultime notizie

12:57 PM

Stock market news: Perspective Therapeutics -44.33%, Pyxis Oncology -42.93% among top losers during mid day trading - Business Upturn

12:57 PM

10:20 AM

Pyxis stock craters 46% amid Phase 1 data, William Blair downgrade (NASDAQ:PYXS) - Seeking Alpha

10:20 AM

10:15 AM

Stock market today: Pyxis Oncology plunges by 47.25% while Perspective Therapeutics declines by 46.68% in early trading - Business Upturn

10:15 AM

10:00 AM

Stock market today: SCWorx Corp. gains 141.81% while Pyxis Oncology down by 46.41% in early trading - Business Upturn

10:00 AM

09:18 AM

Pyxis Oncology's Cancer Drug Progress Stirs Analyst Concerns - Benzinga

09:18 AM

08:38 AM

Pyxis Oncology (NASDAQ:PYXS) Downgraded to "Market Perform" Rating by William Blair - MarketBeat

08:38 AM

08:34 AM

HC Wainwright Reaffirms Buy Rating for Pyxis Oncology (NASDAQ:PYXS) - MarketBeat

08:34 AM

05:23 AM

Institutional investors in Pyxis Oncology, Inc. (NASDAQ:PYXS) lost 11% last week but have reaped the benefits of longer-term growth - Simply Wall St

05:23 AM

Nov 20, 2024

Pyxis Oncology plummets 38% on preliminary phase 1 data for cancer asset - Seeking Alpha

Nov 20, 2024

Pyxis Oncology Reports Promising Phase 1 Trial Results - TipRanks

Nov 20, 2024

Pyxis Oncology announces preliminary PYX-201 data, collaboration with Merck - TipRanks

Nov 20, 2024

Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data - The Manila Times

Nov 20, 2024

Pyxis Oncology, Inc. Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data - Marketscreener.com

Nov 20, 2024

Nov 18, 2024

Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives $9.57 Consensus Target Price from Analysts - MarketBeat

Nov 18, 2024

Nov 17, 2024

Pyxis Oncology, Inc. (NASDAQ:PYXS) Short Interest Up 19.3% in October - MarketBeat

Nov 17, 2024

Nov 15, 2024

Pyxis Oncology FY2024 EPS Forecast Lowered by HC Wainwright - MarketBeat

Nov 15, 2024

FY2024 EPS Estimates for Pyxis Oncology Reduced by Analyst - MarketBeat

Nov 15, 2024

Nov 13, 2024

Laurion Capital Management LP Adjusts Stake in Pyxis Oncology Inc - GuruFocus.com

Nov 13, 2024

Nov 12, 2024